The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin
Cempra Pharmaceuticals appears to be one of the first companies exploring the newly enacted “limited use” pathway for novel antibiotics. The company cited the approach as an option for fusidic acid for use against MRSA – but it sounds like it may also be on the table for the company’s recently rejected solithromycin.
You may also be interested in...
The biotech now only needs to investigate liver toxicity in 6,000 patients – down from 9,000 – to refile its NDA, but Cempra made clear that it won't initiate the study without an external funding source.
Broad spectrum antibiotic candidates for hospital use dominate the late-stage pipeline under the US FDA's Qualified Infectious Disease Product (QIDP) program, despite efforts to target limited populations of patients and pathogens.
Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.